PT - JOURNAL ARTICLE AU - Qibin Liu AU - Xuemin Fang AU - Lu Tian AU - Naveen Vankadari AU - Xianxiang Chen AU - Ke Wang AU - Dan Li AU - Xiyong Dai AU - Feng Xu AU - Lei Shen AU - Bing Wang AU - Li Yao AU - Peng Peng TI - Arbidol treatment with reduced mortality of adult patients with COVID-19 in Wuhan, China: a retrospective cohort study AID - 10.1101/2020.04.11.20056523 DP - 2021 Jan 01 TA - medRxiv PG - 2020.04.11.20056523 4099 - http://medrxiv.org/content/early/2021/03/22/2020.04.11.20056523.short 4100 - http://medrxiv.org/content/early/2021/03/22/2020.04.11.20056523.full AB - BACKGROUND The worldwide COVID-19 pandemic is increasing exponentially and demands an effective and promising therapy at most emergency.METHODS We have assembled a cohort consisting 504 hospitalized COVID-19 patients. Detailed information on patients’ characteristics and antiviral medication use during their stay at designated hospitals along with their pre and post treatment results were collected. The study objective is to evaluate the treatment efficacy of Arbidol, together with the concurrent drugs Oseltamivir and Lopinavir/Ritonavir on mortality and lesion absorption based on chest CT scan.FINDINGS The overall mortality rate was 15.67% in the cohort. The older age, lower SpO2 level, larger lesion, early admission date, and the presence of pre-existing conditions were associated with higher mortality. After adjusting for the patients age, sex, pre-existing condition, SpO2, lesion size, admission date, hospital, and concurrent antiviral drug use, Arbidol was found promising and associated with reduced mortality. The OR for Arbidol is 0·183 (95% CI, 0·075 to 0·446; P<0·001). Furthermore, Arbidol is also associated with faster lesion absorption after adjusting for patient’s characteristics and concurrent antiviral drug use (P=0·0203).INTERPRETATION The broad-spectrum antiviral drug Arbidol was found to be associated with fasterCompeting Interest StatementThe authors have declared no competing interest.Funding StatementThe authors report no funding.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data used to support the findings of this study are available from the corresponding author upon request.